BHC(SH:600721) Sou Hu Cai Jing·2025-08-22 08:16Core Insights - The stock price of Baihua Pharmaceutical (600721) closed at 8.75 yuan on August 22, 2025, reflecting a 1.51% increase with a turnover rate of 10.64% and a trading volume of 409,000 hands, amounting to 357 million yuan in transaction value [1] Financial Performance - For the first half of 2025, Baihua Pharmaceutical reported total operating revenue of 202 million yuan, representing a year-on-year growth of 2.95% [1] - The net profit attributable to shareholders was 25.48 million yuan, showing a year-on-year increase of 12.45% [1] - The company's non-recurring net profit was 24.06 million yuan, up by 13.82% year-on-year [1] - Key financial ratios include a current ratio of 2.026, a quick ratio of 1.722, and a debt-to-asset ratio of 29.66% [1] Capital Flow - On the trading day, the net inflow of main funds was 41.48 million yuan, accounting for 11.63% of the transaction value [1] - Large orders saw a net inflow of 26.36 million yuan, representing 7.39% of the transaction value, while small orders experienced a net outflow of 50.62 million yuan, which is 14.19% of the transaction value [1] Company Background - Xinjiang Baihua Village Pharmaceutical Group Co., Ltd. was established in 1996 and is primarily engaged in wholesale activities [2] - The company has a registered capital of 3.82 billion yuan and a paid-in capital of 481.15 million yuan [1] - The legal representative of the company is Zheng Caihong [1]